Biocon’s insulin to be sold in Mexico

Our Bureau Bengaluru | Updated on January 23, 2018 Published on April 09, 2015

Biopharmaceutical company Biocon Ltd announced on Thursday that its Insulin Glargine has been approved by COFEPRIS, the Mexican health authority, through its partner PiSA Farmaceutica (PiSA). Mexico has been a very important market for Biocon since 2006. Biocon Chairperson & Managing Director Kiran Mazumdar-Shaw said: “Our Insulin Glargine, will now enable access to a basal insulin which will further expand the diabetes management therapy for patients in Mexico.”

Published on April 09, 2015
This article is closed for comments.
Please Email the Editor